Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
14 June 2019Americas

GSK unites with CRISPR pioneer Doudna

British-based pharmaceutical company GSK has entered into a five-year collaboration with the U niversity of California to explore how gene mutations cause disease and accelerate drug discovery.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.

More on this story

Americas
GSK unites with 23andMe amid R&D revamp
27 July 2018   GSK revealed its new approach to research and development earlier this week, including a partnership with DNA testing company 23andMe.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers